Breakout Setups
CYTK appears in our Breakout Setups screen. This means the stock shows strong technical strength, a constructive consolidation pattern, and enough volatility to support a potential breakout if price moves above resistance.
CYTOKINETICS INC (CYTK) Stock Price & Overview
NASDAQ:CYTK • US23282W6057
Current stock price
65.8 USD
-0.34 (-0.51%)
At close:
65.8 USD
0 (0%)
After Hours:
The current stock price of CYTK is 65.8 USD. Today CYTK is down by -0.51%. In the past month the price increased by 7.96%. In the past year, price increased by 62.75%.
CYTK Key Statistics
52-Week Range29.31 - 70.98
Current CYTK stock price positioned within its 52-week range.
1-Month Range59.03 - 68.71
Current CYTK stock price positioned within its 1-month range.
- Market Cap
- 8.104B
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -6.56
- Dividend Yield
- N/A
CYTK Stock Performance
Today
-0.51%
1 Week
-0.83%
1 Month
+7.96%
3 Months
+3.77%
Longer-term
6 Months +13.78%
1 Year +62.75%
2 Years +7.31%
3 Years +75.94%
5 Years +158.65%
10 Years +708.35%
CYTK Stock Chart
CYTK Stock Screens
CYTK currently appears in the following ChartMill screener lists.
CYTK Technical Analysis
ChartMill assigns a technical rating of 7 / 10 to CYTK. When comparing the yearly performance of all stocks, CYTK is one of the better performing stocks in the market, outperforming 85.27% of all stocks.
Chartmill TA Rating
Chartmill Setup Rating
CYTK Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to CYTK. Both the profitability and financial health of CYTK have multiple concerns.
Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
CYTK Earnings
On February 24, 2026 CYTK reported an EPS of -1.5 and a revenue of 17.75M. The company missed EPS expectations (-0.97% surprise) and beat revenue expectations (151.88% surprise).
Next Earnings DateApr 30, 2026
Last Earnings DateFeb 24, 2026
PeriodQ4 / 2025
EPS Reported-$1.50
Revenue Reported17.755M
EPS Surprise -0.97%
Revenue Surprise 151.88%
CYTK Forecast & Estimates
26 analysts have analysed CYTK and the average price target is 96.18 USD. This implies a price increase of 46.17% is expected in the next year compared to the current price of 65.8.
For the next year, analysts expect an EPS growth of -0.63% and a revenue growth 15.78% for CYTK
Analysts
Analysts80.77
Price Target96.18 (46.17%)
EPS Next Y-0.63%
Revenue Next Year15.78%
CYTK Groups
Sector & Classification
CYTK Financial Highlights
Over the last trailing twelve months CYTK reported a non-GAAP Earnings per Share(EPS) of -6.56. The EPS decreased by -24.71% compared to the year before.
Income Statements
Revenue(TTM)88.04M
Net Income(TTM)-784.96M
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -55.1% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
Chartmill High Growth Momentum
EPS Q2Q%-19.05%
Sales Q2Q%4.89%
EPS 1Y (TTM)-24.71%
Revenue 1Y (TTM)376.56%
CYTK Ownership
Ownership
Inst Owners113.45%
Shares123.16M
Float119.42M
Ins Owners0.58%
Short Float %13.27%
Short Ratio8.17
CYTK Competitors/Peers
The largest stocks on the US markets in the "Biotechnology" sub-industry
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 13.83 | 360.314B | ||
| AMGN | AMGEN INC | 15.1 | 188.978B | ||
| GILD | GILEAD SCIENCES INC | 15.08 | 168.645B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.42 | 111.71B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.94 | 79.228B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 45.19 | 41.489B | ||
| INSM | INSMED INC | N/A | 30.828B | ||
| NTRA | NATERA INC | N/A | 29.443B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 28.978B | ||
| BIIB | BIOGEN INC | 11.53 | 26.907B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.62 | 25.134B | ||
| MRNA | MODERNA INC | N/A | 21.65B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 19.477B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About CYTK
Company Profile
Cytokinetics, Inc. is a biopharmaceutical company, which is focused on discovering, developing, and commercializing muscle activators and muscle inhibitors as potential treatments for people with debilitating diseases in which muscle performance is compromised and/or declining. The company is headquartered in South San Francisco, California and currently employs 673 full-time employees. The company went IPO on 2004-04-29. The firm is engaged in the commercialization of aficamten, a cardiac myosin inhibitor, and is being evaluated in additional clinical trials enrolling patients with obstructive and non-obstructive hypertrophic cardiomyopathy. The firm is also developing omecamtiv mecarbil, a cardiac myosin activator, in patients with heart failure with severely reduced ejection fraction (HFrEF); CK-586, a cardiac myosin inhibitor for the potential treatment of heart failure with preserved ejection fraction (HFpEF) and CK-089, a fast skeletal muscle troponin activator with potential therapeutic application to a specific type of muscular dystrophy and other conditions of impaired skeletal muscle function.
Company Info
IPO: 2004-04-29
CYTOKINETICS INC
350 Oyster Point Boulevard
South San Francisco CALIFORNIA 94080 US
CEO: Robert I. Blum
Employees: 673
Phone: 16506243000
CYTOKINETICS INC / CYTK FAQ
What does CYTK do?
Cytokinetics, Inc. is a biopharmaceutical company, which is focused on discovering, developing, and commercializing muscle activators and muscle inhibitors as potential treatments for people with debilitating diseases in which muscle performance is compromised and/or declining. The company is headquartered in South San Francisco, California and currently employs 673 full-time employees. The company went IPO on 2004-04-29. The firm is engaged in the commercialization of aficamten, a cardiac myosin inhibitor, and is being evaluated in additional clinical trials enrolling patients with obstructive and non-obstructive hypertrophic cardiomyopathy. The firm is also developing omecamtiv mecarbil, a cardiac myosin activator, in patients with heart failure with severely reduced ejection fraction (HFrEF); CK-586, a cardiac myosin inhibitor for the potential treatment of heart failure with preserved ejection fraction (HFpEF) and CK-089, a fast skeletal muscle troponin activator with potential therapeutic application to a specific type of muscular dystrophy and other conditions of impaired skeletal muscle function.
What is the current price of CYTK stock?
The current stock price of CYTK is 65.8 USD. The price decreased by -0.51% in the last trading session.
Does CYTK stock pay dividends?
CYTK does not pay a dividend.
How is the ChartMill rating for CYTOKINETICS INC?
CYTK has a ChartMill Technical rating of 7 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Is CYTOKINETICS INC (CYTK) stock a good buy?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on CYTK.
Can you provide the market cap for CYTOKINETICS INC?
CYTOKINETICS INC (CYTK) has a market capitalization of 8.10B USD. This makes CYTK a Mid Cap stock.
Can you provide the upcoming earnings date for CYTOKINETICS INC?
CYTOKINETICS INC (CYTK) will report earnings on 2026-04-30.